October 13, 2026

Urgent Need for Federal Policies on Psychedelic-Assisted Therapies

FILE - A grower cuts psilocybin mushrooms to prepare for distribution in Springfield, Ore., Monday, Aug. 14, 2023. (AP Photo/Craig Mitchelldyer, File)

The United States is confronting a significant mental health crisis. Tragically, the federal efforts are not meeting the urgent demands. Statistics reveal that over 130 Americans lose their lives to suicide daily, with veterans accounting for more than 20 of these deaths each day.

Psychedelic-assisted therapies are emerging as promising alternatives for conditions such as treatment-resistant depression, post-traumatic stress disorder, substance use disorders, and generalized anxiety disorder. Yet, instead of accessing these therapies domestically, many veterans and other citizens seek them internationally, underscoring a deficit in U.S. healthcare offerings.

Appreciation is due to the prior Trump administration and the Food and Drug Administration (FDA) for their roles in accelerating research and granting Breakthrough Therapy designations to numerous psychedelic substances, including psilocybin and MDMA. However, it is crucial for more comprehensive action at the federal level to ensure these vital treatments are available to those most in need.

Two years back, the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus solicited feedback on securely embedding psychedelic medicine within U.S. healthcare. Responses revealed that while psychedelics are not universal remedies, when administered within regulated settings, they profoundly impact patients. Hence, establishing national policies to ensure safe use within medical contexts is imperative.

A national framework is vital to guarantee safe and equitable access. Findings from the PATH Caucus seek to encourage legitimate medical advancements while establishing robust frameworks for safety, ethics, and equity. This requires national guidelines for service delivery and credentialing of practitioners.

Stakeholders agree that the nation demands guidance and verification systems before FDA approvals for psychedelic therapies are finalized. Essential components include labeling requirements for these medicines and codifying best practices related to “set and setting,” crisis response, and pre- and post-session integration support.

For psychedelic medicine to realize its full public health potential, Congress and federal agencies must address these crucial aspects directly. The integration of psychedelic-assisted therapies into the American healthcare system is inevitable, making it crucial to focus on secure and effective methods for implementation. This requires establishing comprehensive standards that safeguard patients, ensure equitable access, and provide substantial benefits to individuals enduring severe health challenges.

Jack Bergman, representing Michigan’s 1st Congressional District, is a retired Marine Corps lieutenant general. Lou Correa represents California’s 46th Congressional District. Both serve as co-chairs of the Congressional PATH Caucus.

Copyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

TAGS: